Bacteriophage Esc-CHP-1 Selective E. coli Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for preventing and treating enterohemorrhagic E. coli infections are inadequate due to the rise of antibiotic-resistant bacteria, and existing treatments often harm beneficial bacteria, leading to immunity weakening and side effects.

Innovation Solution

A Myoviridae bacteriophage Esc-CHP-1, isolated from nature and specifically effective against enterohemorrhagic E. coli, is used as an active ingredient in a composition to prevent and treat infections, acting as a disinfectant, drinking water additive, and feed additive, thereby targeting the pathogenic bacteria without affecting residential flora.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotics are used to prevent or treat enterohemorrhagic E. coli infections, then the effectiveness of treatment is improved, but antibiotic-resistant bacteria emerge and beneficial bacteria are harmed

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidantibiotic resistance and harm to beneficial bacteria

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies segmentation by using a specific bacteriophage (Esc-CHP-1) that targets only enterohemorrhagic E. coli strains, separating the treatment effect from broad-spectrum antibiotic effects. This allows selective elimination of pathogenic bacteria while preserving beneficial flora through strain-specific infection mechanisms

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The bacteriophage acts as an intermediary between the treatment goal and the pathogenic bacteria. Instead of using antibiotics that directly kill bacteria but harm beneficial flora, the patent introduces bacteriophage Esc-CHP-1 as a mediator that specifically infects and lyses enterohemorrhagic E. coli through its unique receptor-binding mechanisms

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If broad-spectrum antibiotics are used to treat bacterial infections, then the killing effect on bacteria is improved, but beneficial bacteria are also killed leading to immunity weakening

Engineering Contradiction:

Improvebacterial killing efficiencyVSAvoidimmunity and beneficial bacteria maintenance

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies local quality by endowing the bacteriophage Esc-CHP-1 with specific properties that enable it to recognize and infect only enterohemorrhagic E. coli strains through particular receptor interactions. This localized specificity ensures high killing efficiency against target bacteria while leaving beneficial bacteria unaffected due to their different cellular structures and receptors

Inventive Principle:

Principle #3Local quality

3Object-affected harmful factors

If conventional disinfectants are used to prevent infections, then the disinfection effect is improved, but side effects and harm to beneficial bacteria occur

Engineering Contradiction:

Improveinfection prevention capabilityVSAvoidside effects on beneficial bacteria

Core Design Contradiction:

Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The patent applies inversion by reversing the conventional approach to infection prevention. Instead of using chemical disinfectants that non-selectively kill or inhibit all bacteria, the patent uses a biological agent (bacteriophage Esc-CHP-1) that selectively infects and kills only pathogenic enterohemorrhagic E. coli strains, thereby preventing infections while preserving beneficial bacteria through its inverted selectivity mechanism

Inventive Principle:

Principle #13The other way round (Inversion)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The bacteriophage composition effectively inhibits and kills enterohemorrhagic E. coli, reducing diarrhea and infection severity in both humans and animals, with high specificity and fewer side effects compared to chemical treatments, while maintaining the health of beneficial bacteria.

Implementation Method 1

Once bacteriophage infects bacteria, the bacteriophage is proliferated in the inside of the bacterial cell. After full proliferation, the progenies destroy the bacterial cell wall to escape from the host, suggesting that the bacteriophage has bacteria killing ability.

Methodology Applied

Scientific EffectBacteriophage infection and lysis:

Data Source

PatentUS10265353B2Enterohemorrhagic <i>E. coli </i>bacteriophage Esc-CHP-1 and use thereof for inhibiting proliferation of enterohemorrhagic <i>E. coli</i>

Publication Date: 2019.04.23 INTRON BIOTECHNOLOGY INC

AI summary

The present invention relates to a Myoviridae bacteriophage Esc-CHP-1 that is isolated from the nature and can kill specifically enterohemorrhagic E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12660BP), and a method for preventing and treating the infections of enterohemorrhagic E. coli using the composition comprising said bacteriophage as an active ingredient.